Skip to main content

Kinetics of Re-differentiation with Short-Course Dabrafenib and Trametinib in Patients with Radioiodine-Refractory Thyroid Cancer

In brief

Dabrafenib-trametinib restored iodine uptake within two weeks in 6 of 9 patients

In this 14-patient phase II trial, 9 patients met imaging criteria and received radioiodine; 6 of those 9 regained iodine uptake within two weeks. Among radioiodine-treated patients, 75% had an objective response within six months, and median progression-free survival was 10.8 months. The small study supports testing shorter, individualized treatment, but cannot establish benefit versus longer treatment.

Journal
Clinical cancer research : an official journal of the American Association for Cancer Research (Q1)
Published
9 November 2026
Study design
Non-randomized / quasi-experimental trial
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Samantha Peiling Yang, Kelvin Siu Hoong Loke, Wei Ming Chua, Wan Qin Chong, Min En Nga, Regina Tong Xin Wong, et al.
PMID
43002139
DOI
10.1158/1078-0432.CCR-26-2415

Why clinicians should know about it

Abstract

PURPOSE: MAPK pathway activation suppresses iodine-handling genes, including sodium-iodide symporter (NIS), contributing to loss of iodine avidity in radioiodine-refractory thyroid cancer. Prior BRAF/ MEK inhibitor re-differentiation trials improved iodine uptake but used empiric 4-6 week treatment. The timing of maximal NIS re-expression remains undefined. We evaluated whether short course dabrafenib plus trametinib restores iodine uptake and provides clinical benefit. PATIENTS AND METHODS: In this multicentre phase II trial, patients with progressive metastatic radioiodine-refractory thyroid carcinoma harbouring BRAFV600E or RAS mutations received dabrafenib and trametinib. I-124 PET/CT dosimetry was performed at baseline and after 2 weeks, with repeat imaging at week 4 post therapy if dosimetry criteria was not met. Radioiodine was administered once criteria was met. The primary endpoint was attainment of predicted lesional absorbed dose ≥20 Gy with I-131 activity ≤300 mCi. Secondary endpoints included RECIST response, progression-free survival (PFS), thyroglobulin response, and safety. RESULTS: Nine of 14 patients (64%) met the dosimetry criteria and received radioiodine; 6 out of 9 (67%) restored iodine uptake within 2 weeks. Among radioiodine-treated patients, best objective response rate within 6 months was 75% by RECIST. Median PFS was 10.8 months. RAS-mutant tumours demonstrated greater lesion regression than BRAFV600E-mutant tumours. Early reduction in stimulated thyroglobulin and preserved FOXE1 nuclear localisation, and higher tumour-to-normal GLIS3 nuclear expression were associated with re-differentiation response. CONCLUSIONS: Short-course dabrafenib/ trametinib can induce rapid re-differentiation within 2 weeks in a subset of patients with MAPK-driven radioiodine-refractory thyroid cancer, supporting individualized BRAF/MEK inhibition duration rather than empiric prolonged treatment.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.